Cancel Preloader

Annual Review

Annual Review

Annual Review 2024

Annual Review
2002-2003

Annual Review 2021

Annual Review 2019

Annual Review 2018

Annual Review 2017

Annual Review 2016

Annual Review 2015

Annual Review 2014

Annual Review 2013

Annual Review 2012

Annual Review
2010-2011

Annual Review 2009

Annual Review 2008

Annual Review 2007

Annual Review 2006

Annual Review 2005

Annual Review
2003 – 2004

Annual Review 2002

Annual Review 2001

Annual Review 2020

Annual Review 1999

Annual Review 1998

Highlight

  • “The VTC celebrated 30 years of operation in 2016. Part of the activities to recognize this important achievement was hosting the ThaiTect”

  • 2017 mainly focused on establishing the cohort for a study of men having sex with men (MSM), in preparation and planning to test a new type of HIV vaccine. The modified prime boost regimen using ALVAC and adjuvanted gp120 HIV vaccines and Ad26 “Mosaic” HIV vaccine are currently being tested in Africa as proof-of-concept studies, supported by the US National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation (BMGF). Ad26 mosaic vaccine uses genes from different HIV subtypes in the hope of giving universal immunity against all HIV clades. Knowledge gained at the Vaccine Trial Centre has contributed greatly towards the safety and immune response profile (AD26 vaccine) and timing of the immunization schedule plan used in the African study (RV306- ALVAC-AIDSVAX boosting). Studies carried out by the VTC have shown that a longer period between booster immunizations leads to a better immune response to the vaccine regimen.

  • The Vaccine Trial Centre has contributed towards giving the clinical trial results of the live attenuated avian influenza vaccine (LAIV H5N2) produced by the Government Pharmaceutical Organisation (GPO). The immunity results, together with the immune responses after priming, were used to file for licensing the product and it was approved for emergency

  • The Vaccine Trial Centre is one of the multi centers from around the globe conducting Phase 2 and 3 trials to assess the immunogenicity and       efficacy of the new 9-valent HPV vaccine (9vHPV) among subjects with differing baseline characteristics.

  • Results of a trial by the Vaccine Trial Centre led to the successful licensing of a new acellular pertussis vaccine containing genetically inactivated pertussis toxin in Thailand. Working with Bio Net Asia.
  • The Vaccine Trial Centre has celebrated its 36th year anniversary. To commemorate this special occasion, the Center published a chronological book that encompasses the history and journey of the Center. The book also highlights the work done over the previous 36 years and future plans.

  • The results of RV306 trial was published in the Lancet HIV. RV306 was a double-blind, randomized clinical controlled trial which evaluated the immunological effect of late boosting of RV144 regimen (AIDSVAX B/E and ALVAC-HIV) in HIV-uninfected Thai volunteers, aged 20-40 years. The study demonstrated that combined AIDSVAX B/E and ALVAC-HIV, with longer intervals between the primary vaccination series and late boost, improved immune responses and might also improve the efficacy of preventing HIV acquisition. Boosting regimens of RV305, a HIV vaccine trial designed to evaluate the immunologic impact of late boosting with either the boosting protein antigen alone, the canarypox viral vector ALVAC alone, or a combination of both. The study results were published in the Journal of Infectious Diseases. It was found that IgG1 antibody levels and most functional responses increased upon protein boosting, regardless of the viral vector priming agent combination. This suggests that late protein boost alone is enough to increase functionally potent vaccine-specific antibodies previously associated with a reduced risk of infection with HIV.

  • Research projects
    • The Vaccine Trial Centre completed a phase III double blinded, randomized, controlled, noninferiority trial to evaluate the immunogenicity and safety of trial Fluvac, a seasonal trivalent inactivated split virion influenza vaccine, in healthy Thai subjects aged 65 years and above. The Government Pharmaceutical Organization (GPO), Thailand funded the study.
    • The Centre has an ongoing study clinical trial: a phase II international, multi-center, randomized, double-blind, placebo-controlled clinical trial (V503-049), to study the efficacy, immunogenicity, and safety of the 9vHPV vaccine, a multivalent L1 virus-like particle vaccine, in the prevention of persistent oral infection with HPV types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20-45 years of age. Merck Sharp & Dohme (MSD), a pharmaceutical company, is funding this trial.
    • The National Science and Technology Development Agency (NSTDA) provided funding to the Centre to conduct a phase II/III randomized, observer-blind, active –controlled study (DTA201) to compare the non-inferior immunogenicity of a combined DiptheriaTetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (nonrecombinant), when administered to healthy toddlers aged 18-36 months.
    • HPV021, a 2-year clinical trial that aimed to evaluate the effectiveness of HPV vaccine among women aged 20 years or more, was completed in 2020. Prof. Punnee and team are in the process of publishing the results of their study. The trial was funded by the National Vaccine Institute.
    • Early in 2021, Prof. Punnee Pitisuttithum was granted funding to conduct a phase 1/2 randomized, placebo-controlled, observer-blind trial to assess the safety and immunogenicity of NDV-HXP-S vaccine in Thailand. The NDVHXP-S is the first Thai-made COVID-19 vaccine manufactured by GPO. The trial is estimated to complete in 2023.